Roche 2Q10 2Q10 Revenues: $11.2 billion (flat) YTD Revenues: $22.8 billion (+7%) YTD Earnings: $5.1 billion (+43%) Comments: Pharma sales were down 2% in 2Q10 to $8.7 billion, and were up 6% to $17.9 billion in 1H10. Half-year revenues were driven by Avastin ($3.1 billion), Rituxan ($3.1 billion) and Herceptin ($2.6 billion). The U.S. market accounted for 38% of pharma revenues. As expected, Tamiflu revenues dropped significantly after the previous year’s H1N1 flu-related stock...